DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Ganaxolone
Ganaxolone
Mechanisms of Action of Antiepileptic Drugs
8Th European Congress on Epileptology, Berlin, Germany, 21 – 25 September 2008
Ganaxolone (Epilepsy) – Forecast and Market Analysis to 2022
Molecular Mechanisms of Antiseizure Drug Activity at GABAA Receptors
Effect of Ganaxolone on Seizure Frequency Across Subpopulations of Patients with CDKL5 Deficiency Disorder: Subgroup Analyses of the Marigold Study Elia M
Long-Term, Durable Seizure Frequency Reduction in Children with CDKL5 Deficiency Disorder (CDD) Treated with Ganaxolone
Ganaxolone Significantly Reduces Major
Topline Results from the Marigold Study: Evaluating Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder
Intravenous Ganaxolone for the Treatment of Refractory Status Epilepticus: Results from an Open-Label, Dose-Finding, Phase 2 Study Henrikas Vaitkevicius, MD1,*; R
Epileptogenesis and Epilepsy
Intravenously Administered Ganaxolone Blocks Diazepam- Resistant Lithium
Antiepileptic Potential of Ganaxolone Antiepileptički Potencijal Ganaksolona
Pharmacology of Antiepileptic Drugs
WO 2015/181797 Al 3 December 2015 (03.12.2015) P O P C T
Us 2019 / 0160078 A1
Novel Antiepileptic Drugs
Comparison with Allopregnanolone S
Mechanism-Based Novel Antidotes for Organophosphate Neurotoxicity Doodipala Samba Reddy
Top View
Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
A Randomized Controlled Trial of Ganaxolone in Posttraumatic Stress Disorder
Intravenous Ganaxolone Achieves Rapid and Dose-Dependent Sustained Improvement in EEG Seizure Burden in Patients with Refractory Status Epilepticus Authors: Aatif M
Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
Ganaxolone Achieves Primary Endpoint in Phase 3 Trial for CDKL5 De Ciency Disorder (CDD), a Rare Form of Genetic Epilepsy
Ganaxolone Improves Behavioral Deficits in a Mouse Model of Post
View Annual Report
Original Article
Corporate Overview
(Gnx) Mechanism of Action Phase
Adaptive Immune Response in Epilepsy
The Anticonvulsant Retigabine Is a Subtype Selective Modulator of GABAA Receptors
Ion Channels Product Listing | Edition 1
IV Ganaxolone in Pediatric Super
Ganaxolone Product Analysis
Benefit of Topiramate in the Treatment of Symptoms of Borderline Personality Disorder: a Typical Review
Sedative and Neurotoxic Properties of Brexanolone Compared to Midazolam in the Developing Rodent Brain
Stress and Drug Abuse-Related Disorders the Promising
Brain Sciences
Evaluation of Anti - Anxiety, Sedative and Motor Co-Ordination Properties of Ganaxolone in Comparison with Diazepam in Rodent Models
Newer Anti-Epileptic Drugs
Harmonized Tariff Schedule of the United States (2006) (Rev
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
IV Ganaxolone in Refractory Status Epilepticus (RSE): Phase 2 Clinical Data & Phase 3 Planning
Appendix E-3: Complete Search Strategy
The Endocrine System and Alcohol Drinking in Females
Ganaxolone: Mechanism of Action and Pharmacology
WO 2U11/132171 Al
Development of Parenteral Drugs for the Treatment of Seizure Emergencies
Neurosteroid Replacement Therapy for Catamenial Epilepsy
Supplementary Material
Epilepsia 2017, 58(4):558-564
WO 2019/094724 Al 16 May 2019 (16.05.2019) W P O PCT
Marinus Investor Presentation
Ethanol 40 L-Glutamic Acid 39 Zonisamide 30 Picrotoxin 22
Pharmaceuticals Appendix
Intravenously Administered Ganaxolone Blocks Diazepam- Resistant Lithium-Pilocarpine–Induced Status Epilepticus in Rats: Comparison with Allopregnanolone S
Pharmacotherapy of Catamenial Epilepsy
Treatment of Super Refractory Status Epilepticus Using Intravenous
Ganaxolone in CDKL5 Deficiency Disorder: Open-Label Phase 2A Results and Ongoing Pivotal Phase 3 Study Design
Tuberous Sclerosis Complex
WO 2016/127170 Al 11 August 2016 (11.08.2016) P O P C T
Fda's Rocket Docket
Antiepileptic Drugs and Migraine